ARTICLE | Clinical News
Undisclosed cardiovascular compound: Development discontinued
April 23, 2012 7:00 AM UTC
Actelion disclosed in its 1Q12 earnings that it would not pursue cardiovascular indications, such as essential hypertension or stable angina, for an undisclosed cardiovascular compound after a proof-o...